IMA — Stock Film
STOCK FILMSCENE 1/11IMA · $5.66
Stock Expert AI presents
IMA
ImageneBio Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
ImageneBio Inc. A quick introduction.

On the stock market since 1998, it operates in the world of health and science. It has 15 employees. Now — the numbers.

on the stock market since 1998
15 employees
$64.4M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $58.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 60% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$31M
2021
$15.6M
2022
$9.2M
2023
$3.5M
2024
$800K
2025
In the vault right now:
$0
DEBT: $10.0M
At this pace, that money lasts about 1.7 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
28
very weak

Clearly below the class average.

FINANCIAL STRENGTH
55
average

The cash pile is strong; debt and other items pull the grade toward the middle.

VALUATION
72
strong

Clearly above the class average — a step short of the very top.

GROWTH
11
very weak

Clearly below the class average.

PRICE MOMENTUM
25
very weak

Clearly below the class average.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
WEAK SPOTS
The stock has lost its spark0/10
Growth has stalled2/10
Each sale is made at a loss3/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $75.8M in the vault; even if every debt were paid off, $65.8M would remain.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 35 buys and 4 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $45.3M against $800K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
The cash has a countdown

At the current pace of spending, the cash lasts about 1.7 years. After that, the company needs to find new money.

3
THE RISKS · 3/3
The price sits above analysts’ target

The stock trades 77% above the average analyst price target.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, IMA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: IMA is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film